High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease

Journal of the American College of Cardiology

Volumn 61, Issue 9, 2013, Pages 926-932

  Rekhraj, Sushma ^a   Gandy, Stephen J ^a   Szwejkowski, Benjamin R ^a   Nadir, M Adnan ^a   Noman, Awsan ^a   Houston, J Graeme ^a   Lang, Chim C ^a   George, Jacob ^a   Struthers, Allan D ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

allopurinol; ischemic heart disease; oxidative stress; ventricular hypertrophy

Indexed keywords

ALLOPURINOL; PLACEBO;

ADULT; AGED; ARTERIAL STIFFNESS; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; ENDOTHELIUM; FEMALE; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART VENTRICLE HYPERTROPHY; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TONOMETRY;

AGED; ALLOPURINOL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MAGNETIC RESONANCE IMAGING; MALE; MANOMETRY; MYOCARDIAL ISCHEMIA;

EID: 84875460112     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2012.09.066     Document Type: Article

References (27)

1. D.S. Ang, S.D. Pringle, A.D. Struthers The cardiovascular risk factor, left ventricular hypertrophy, is highly prevalent in stable, treated angina pectoris Am J Hypertens 20 2007 1029 1035
2. P. Gosse Left ventricular hypertrophy-the problem and possible solutions J Int Med Res 33 Suppl 1 2005 3A 11A
3. Y. Liao, R.S. Cooper, D.L. McGee, G.A. Mensah, J.K. Ghali The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults JAMA 273 1995 1592 1597
4. S.M. Artham, C.J. Lavie, R.V. Milani, D.A. Patel, A. Verma, H.O. Ventura Clinical impact of left ventricular hypertrophy and implications for regression Prog Cardiovasc Dis 52 2009 153 167
5. P.M. Okin, R.B. Devereux, S. Jern Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events JAMA 292 2004 2343 2349
6. P. Verdecchia, F. Angeli, C. Borgioni Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis Am J Hypertens 16 2003 895 899
7. R.B. Devereux, B. Dahlof, E. Gerdts Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial Circulation 110 2004 1456 1462
8. J.T. Laakso, T.L. Teravainen, E. Martelin, T. Vaskonen, R. Lapatto Renal xanthine oxidoreductase activity during development of hypertension in spontaneously hypertensive rats J Hypertens 22 2004 1333 1340
9. X. Xu, X. Hu, Z. Lu Xanthine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in mice J Card Fail 14 2008 746 753
10. N. Engberding, S. Spiekermann, A. Schaefer Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug? Circulation 110 2004 2175 2179
11. M.P. Kao, D.S. Ang, S.J. Gandy Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease J Am Soc Nephrol 22 2011 1382 1389
12. N.S. Rajendra, S. Ireland, J. George, J.J. Belch, C.C. Lang, A.D. Struthers Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris J Am Coll Cardiol 58 2011 820 828
13. R.M. Lang, M. Bierig, R.B. Devereux Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology J Am Soc Echocardiogr 18 2005 1440 1463
14. M.C. Corretti, T.J. Anderson, E.J. Benjamin Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force J Am Coll Cardiol 39 2002 257 265
15. J. George, E. Carr, J. Davies, J.J. Belch, A. Struthers High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid Circulation 114 2006 2508 2516
16. F. Grothues, G.C. Smith, J.C. Moon Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy Am J Cardiol 90 2002 29 34
17. D.I. Jalal, K.L. Jablonski, K. McFann, M.B. Chonchol, D.R. Seals Vascular endothelial function is not related to serum uric acid in healthy adults Am J Hypertens 25 2012 407 413
18. G. Schillaci Pharmacogenomics of left ventricular hypertrophy reversal: beyond the 'one size fits all' approach to antihypertensive therapy J Hypertens 22 2004 2273 2275
19. G.B. Mancini, B. Dahlof, J. Diez Surrogate markers for cardiovascular disease: structural markers Circulation 109 2004 IV22 IV30
20. R.B. Devereux, K. Wachtell, E. Gerdts Prognostic significance of left ventricular mass change during treatment of hypertension JAMA 292 2004 2350 2356
21. P.M. Okin, K. Wachtell, R.B. Devereux Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension JAMA 296 2006 1242 1248
22. P.M. Okin, R.B. Devereux, K.E. Harris Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients Ann Intern Med 147 2007 311 319
23. E. Takimoto, D.A. Kass Role of oxidative stress in cardiac hypertrophy and remodeling Hypertension 49 2007 241 248
24. J. Hashimoto, Y. Imai, M.F. O'Rourke Indices of pulse wave analysis are better predictors of left ventricular mass reduction than cuff pressure Am J Hypertens 20 2007 378 384
25. A. Noman, D.S. Ang, S. Ogston, C.C. Lang, A.D. Struthers Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial Lancet 375 2010 2161 2167
26. E. Rentoukas, K. Tsarouhas, C. Tsitsimpikou, G. Lazaros, S. Deftereos, S. Vavetsi The prognostic impact of allopurinol in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention Int J Cardiol 145 2010 257 258
27. M. Goicoechea, S.G. de Vinuesa, U. Verdalles Effect of allopurinol in chronic kidney disease progression and cardiovascular risk Clin J Am Soc Nephrol 5 2010 1388 1393